PDYN vs ISRG vs NVDA vs SYK vs ZBH

For growth investors, NVIDIA Corporation (NVDA) is the stronger pick with 65.

5% revenue growth year-over-year, versus -32. 6% for Palladyne AI Corp. (PDYN). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 5x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zimmer Biomet Holdings, Inc.

(ZBH) is the cheapest at 23. 5x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: NVIDIA Corporation wins at 0. 27x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, NVIDIA Corporation (NVDA) delivered a total return of +1329%, compared to -88.

7% for Palladyne AI Corp. (PDYN). Over 10 years, the gap is even starker: NVDA returned +239. 0% versus PDYN's -88. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus Palladyne AI Corp. 's 3. 07β — meaning PDYN is approximately 461% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NVIDIA Corporation (NVDA) is pulling ahead at 65.

5% versus -32. 6% for Palladyne AI Corp. (PDYN). On earnings-per-share growth, the picture is similar: Palladyne AI Corp. grew EPS 108. 7% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, NVDA leads at 100. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Palladyne AI Corp.

(PDYN) is the more profitable company, earning 191. 4% net margin versus 8. 6% for Zimmer Biomet Holdings, Inc. — meaning it keeps 191. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVDA leads at 60. 4% versus -617. 7% for PDYN. At the gross margin level — before operating expenses — NVDA leads at 71. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, NVIDIA Corporation (NVDA) is the more undervalued stock at a PEG of 0. 27x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Zimmer Biomet Holdings, Inc. (ZBH) trades at 9. 8x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 34. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PDYN: 54. 5% to $9. 50.

In this comparison, ZBH (1.

1% yield), SYK (1. 1% yield) pay a dividend. PDYN, ISRG, NVDA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Palladyne AI Corp. (PDYN) carries a higher beta of 3. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, PDYN: -88. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PDYN (Technology) and ISRG (Healthcare) and NVDA (Technology) and SYK (Healthcare) and ZBH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PDYN is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVDA is a mega-cap high-growth stock; SYK is a mid-cap quality compounder stock; ZBH is a mid-cap quality compounder stock. SYK, ZBH pay a dividend while PDYN, ISRG, NVDA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.